Lung-Homing of Endothelial Progenitor Cells and Airway Vascularization Is Only Partially Dependant on Eosinophils in a House Dust Mite-Exposed Mouse Model of Allergic Asthma

Nirooya Sivapalan, Jennifer Wattie, Mark D. Inman, Roma Sehmi*

Asthma Research Group, Firestone Institute for Respiratory Health, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada

Abstract

Background: Asthmatic responses involve a systemic component where activation of the bone marrow leads to mobilization and lung-homing of progenitor cells. This traffic may be driven by stromal cell derived factor-1 (SDF-1), a potent progenitor chemoattractant. We have previously shown that airway angiogenesis, an early remodeling event, can be inhibited by preventing the migration of endothelial progenitor cells (EPC) to the lungs. Given intranasally, AMD3100, a CXCR4 antagonist that inhibits SDF-1 mediated effects, attenuated allergen-induced lung-homing of EPC, vascularization of pulmonary tissue, airway eosinophilia and development of airway hyperresponsiveness. Since SDF-1 is also an eosinophil chemoattractant, we investigated, using a transgenic eosinophil deficient mouse strain (PHIL) whether EPC lung accumulation and lung vascularization in allergic airway responses is dependent on eosinophilic inflammation.

Methods: Wild-type (WT) BALB/c and eosinophil deficient (PHIL) mice were sensitized to house dust mite (HDM) using a chronic exposure protocol and treated with AMD3100 to modulate SDF-1 stimulated progenitor traffic. Following HDM challenge, lung-extracted EPCs were enumerated along with airway inflammation, microvessel density (MVD) and airway methacholine responsiveness (AHR).

Results: Following Ag sensitization, both WT and PHIL mice exhibited HDM-induced increase in airway inflammation, EPC lung-accumulation, lung angiogenesis and AHR. Treatment with AMD3100 significantly attenuated outcome measures in both groups of mice. Significantly lower levels of EPC and a trend for lower vascularization were detected in PHIL versus WT mice.

Conclusions: This study shows that while allergen-induced lung-homing of endothelial progenitor cells, increased tissue vascularization and development lung dysfunction can occur in the absence of eosinophils, the presence of these cells worsens the pathology of the allergic response.

Citation: Sivapalan N, Wattie J, Inman MD, Sehmi R (2014) Lung-Homing of Endothelial Progenitor Cells and Airway Vascularization Is Only Partially Dependant on Eosinophils in a House Dust Mite-Exposed Mouse Model of Allergic Asthma. PLoS ONE 9(10): e109991. doi:10.1371/journal.pone.0109991

Editor: Rossana C.N. Melo, Universidade Federal de Juiz de Fora, Brazil

Received May 7, 2014; Accepted September 14, 2014; Published October 3, 2014

Copyright: © 2014 Sivapalan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files (see attached excel file entitled all data).

Funding: This work was supported by a grant-in-aid from the Canadian Lung Association. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: sehmir@mcmaster.ca

Introduction

Despite the development of effective anti-inflammatory therapies and improved delivery approaches, airflow obstruction in asthma is often not fully reversible, and many asthmatics experience an accelerated and progressive loss of lung function over time. Histopathological studies of resected lung and bronchial biopsies have demonstrated several stereotypic changes that correlated with asthma severity [1] suggesting that remodelling of the airway wall may have profound functional consequences, perhaps even greater than those associated with inflammation [2] [3].

Angiogenesis (formation of new blood vessels) in the bronchial submucosa is one of the most consistent features of the asthmatic lung and has been shown to be associated with disease severity [1,4–7]. However, despite an increasing interest, the contribution of the microvascular bed to airway remodelling in asthma is not fully elucidated [8]. It is proposed that increased vascularity assessed as increased vessel number and increased vessel engorge-ment, can directly increase airway wall thickness causing airway luminal narrowing and facilitate inflammatory cell trafficking thus contributing to airflow obstruction and development of airway hyperresponsiveness (AHR) [9,10]. Investigating the biological processes by which angiogenesis occurs in asthma may provide novel therapeutic targets for the treatment of asthma pathology and understanding its contribution to the development of difficult
to control symptoms such as the progressive decline in lung function. It has been proposed that post natal angiogenesis, is a complex process whereby new blood vessels sprouting from extant microvasculature can arise either from the proliferation of resident mature vascular endothelial cells and/or as a result of the lung-homing of endothelial progenitor cells (EPC) from the BM [11–13]. The literature indicates that EPC have the potential to produce growth factors that stimulate local angiogenic responses in a paracrine fashion or incorporate into existing microvessels thus acting as building blocks to form new vasculature [4,12,14]. Regardless of the exact role of these progenitor cells, increased mobilization of EPC have been detected in several inflammatory lung conditions including atopic asthma [15]. In asthmatics, EPC numbers are increased in number in the peripheral blood and demonstrate a more proliferative phenotype with the potential to form more tubelike capillary structures in culture, compared to normal nonatopic subjects [13]. More recently, we have shown that following allergen inhalation challenge in asthmatics who develop airway eosinophilia and delayed AHR greater numbers of sputum-extracted EPCs and increased vessel numbers and size in endo-bronchial biopsies were detected [16]. Although studies have reported that CXCR2 ligands promote lung-homing of EPC [17] and that IL-25 and thymic stromal lymphopoietin (TSLP) may promote angiogenic responses [18] [19], mechanisms that orchestrate lung accumulation of EPC in allergic asthma have not been fully investigated.

Using both acute- and chronic-Ag (Ag) exposure protocols, a rapid and sustained increase in microvessel density (MVD) within the lungs of BALB/c mice has been reported [15]. These changes correlated directly and closely with increased airway responsiveness and EPC lung accumulation. In further studies, using the fact that stromal cell derived factor-1 (SDF-1) is a potent progenitor cell chemoattractant, we treated mice with AMD3100 or saline vehicle was administered 4 h before each brief allergen exposure protocol [20]. This treatment inhibited Ag-induced EPC lung-homing, vascularization, airway eosinophilia and development of AHR. Since SDF-1 is also an eosinophil chemoattractant, and it has been shown that eosinophils produce factors, it remains unclear as to whether AMD3100 acted directly on the progenitor cells. In addition, this study shows that while Ag-induced lung accumulation of EPC and increased lung vascularization occur in the absence of eosinophils, the presence of these cells may have a role in worsening of the pathology of allergic airways disease.

Materials and Methods

Ethics Statement

All procedures were reviewed and approved by the Animal Research Ethics Board at McMaster University (Hamilton, ON, Canada). The protocol was approved by the Committee on the Animal Ethics Review Board, McMaster University, Hamilton (Permit number AUP # 10-12-76). All surgery was performed under sodium pentobarbital anesthesia to minimize suffering.

Animals

Female BALB/c and PHIL eosinophil-deficient mice (BALB/c background) were bred and maintained in a pathogen-free environment. PHIL eosinophil-deficient male mice (8th generation BALB/c background; courtesy of Dr. J.J. Lee) were mated with WT BALB/c females (8 week old; Charles River Laboratories, Ottawa, ON). Female PHIL eosinophil-deficient mice (8 week old) and WT littermate controls were kept in a pathogen-free environment.

Allergen Exposure- Chronic Exposure Protocol

Mice (PHIL or WT; n = 10/group) were sensitised and challenged as previously described [22] with modification (Figure 1). Briefly, mice were exposed to HDM Dermatophagoides pteronyssinus extract (Greer Laboratories, Lenoir, NC) intranasally (i.n.) (25 μg in 35 μL) for 5 days per week for two weeks, followed by every other day exposures, weekly, for 6 weeks. Outcomes were measured at day 57 (24 h post final exposure).

Treatment Intervention

Mice were given AMD3100 i.n. (Sigma, Mississauga, ON, Canada), a CXCR4 antagonist [23]. Optimal dosing of the drug (15 mg/Kg) was previously established as the lowest dose capable of attenuating allergen-induced increases in airway vascularity in a brief allergen exposure protocol [20]. Concurrent treatment with AMD3100 or saline vehicle was administered 4 h before each allergen challenge during days 13–56 of exposure (Fig. 1).

Airway Methacholine Responsiveness

Airway responsiveness to intravenous methacholine (MCh) was measured based on the response of airway resistance using the FlexiVent ventilator system (SCIREQ, Montreal, QC, Canada), as previously described [22]. Maximal airway resistance was calculated in response to up to 25 mg/mL methacholine i.n. (n = 10 per group).

Bronchoalveolar Lavage

Bronchoalveolar lavage (BAL) and differential cell counts were performed as previously described in detail [24].

Progenitor Cell Isolation, Immunostaining and Flow Cytometry

Mice were sacrificed by exsanguination via cardiac puncture and lungs were perfused clear of blood with saline and removed from the thoracic cavity, as previously described [25]. Lung tissue-associated cells were extracted from the right lung by mincing and enzymatic digestion, as previously described [20]. Mononuclear cells were collected following density gradient centrifugation (400 g for 20 min) over Histopaque (Sigma, Oakville, Ontario, Canada).

Cells were immunostained with Sca-1-FITC, c-kit-PE (BD Bioscience, Oakville, ON, Canada) and VEGFR2-APC (eBioscience Inc., San Diego, CA, USA), or isotype control
obtained by flow cytometry and the total white cell count. Were calculated using the percentage of population positivity in detail in [15]. Doyle et al., 2011 [20]. Absolute numbers of cells were enumerated using the Cellquest software package (BD Biosciences). The flow cytometric gating strategy are previously described in [15]. Doyle et al., 2011 [20]. Absolute numbers of cells were calculated using the percentage of population positivity obtained by flow cytometry and the total white cell count.

Lung Histology and Morphometry
The left lung was perfused with saline, formalin fixed, embedded in paraffin and cut into 3-μm sections. Bronchial vascularity was identified by staining with polyclonal rabbit antihuman von Willebrand factor (vWF) (Dako, Carpinteria, CA, USA), which cross-reacts with the mouse antigen [26]. Slides were analysed using a customised digital image analysis system (Northern Eclipse; Empix Imaging, Mississauga, ON, Canada). The main airway in the tissue section was identified and traced, allowing the program to only identify the area within a 50 μm bandwidth from the airway. Only vessels that were vWF+ within this area and less than 10 μm in diameter were included in vessel quantification. Microvessel density (MVD) was then calculated by dividing the total positive vessels by the bandwidth area. Fixed lung sections (3 μm) were also stained with hematoxylin and eosin (H&E) to identify tissue eosinophils. Eosinophils within a 50-μm bandwidth from the main airway were enumerated and calculated as total number of eosinophils per bandwidth area using Northern Eclipse software.

Cytokine/Chemokine Assessments
Lung tissue supernatants were analyzed by ELISA, vascular endothelial growth factor (VEGF) and SDF-1, TSLP, IL-25 and IL-33 kits (R&D Systems, Minneapolis, MN, USA). All data were normalized for lung weight.

Statistical Analysis
Data are presented as mean ± SEM. Analysis was performed using STATISTICA software (Statsoft INC., Tulsa, OK, USA) to perform ANOVAs; post hoc analyses for between groups comparisons were performed using Duncan’s test. Alpha was set at 0.05.

Results
Progenitor Cells: HDM exposure stimulated progenitor cell lung accumulation which was inhibited by treatment with AMD3100 in WT and PHIL mice
Using a chronic allergen exposure model in WT and PHIL BALB/c mice, primitive progenitor cells (PC; Sca-1+ c-kit+) and endothelial progenitors (EPC; Sca-1+ c-kit VEGERF2+VEGFR2+) were enumerated in lung-extracted tissue, 24 h post-challenge with allergen (HDM) or saline (SAL) (Fig. 2 & 3). Compared to SAL, PC levels were significantly increased following HDM exposure in WT and PHIL mice (Fig. 2). Similarly, compared to SAL, EPC levels were significantly increased following HDM exposure in WT and PHIL mice (Fig. 3). Between group comparisons showed that PHIL/HDM exposed mice had a significantly lower numbers of lung extracted PC (Fig. 2) and EPC (Fig. 3). Intranasal administration of AMD3100 given concurrently with HDM exposure significantly attenuated lung PC (Fig. 2) and EPC numbers (Fig. 3) to SAL levels in both groups of mice. In control experiments performed in PHIL mice, we found there was no difference between HDM treated group vs HDM/vehicle group which supported a specific effect of AMD3100.

Angiogenesis: HDM exposure increased bronchial vascularity which was attenuated by treatment with AMD3100 in WT and PHIL mice
Lung vascularity was assessed by staining for vWF in mouse lung slices and enumerating microvessel density (MVD) (Fig. 4). MVD was significantly increased in HDM when compared to SAL groups for both WT and PHIL mice (Fig. 4). In WT mice, compared to the HDM group treatment with AMD3100 (HDM/AMD group) significantly attenuated MVD levels although these levels remained significantly greater than SAL levels. Similarly in PHIL mice, AMD3100 treatment significantly attenuated MVD levels compared to HDM group and these levels were comparable with SAL levels (Fig. 4). A vehicle effect was not observed in PHIL mice supporting a specific effect of AMD3100.

Between group comparisons showed a trend towards lower lung vascularity in PHIL/HDM mice compared to WT/HDM group (p = 0.058) (Fig. 4).
Airway Inflammation: Eosinophilia in WT mice was significantly attenuated in lung tissue when allergen-exposed mice were treated with AMD3100.

To assess for tissue eosinophilia, lung sections were stained with hematoxylin and eosin. In WT mice, there was a significant increase in eosinophils in the HDM group compared to SAL and these levels were attenuated in the AMD3100 treated group, though not to SAL levels (Fig. 5). As expected, PHIL mice had negligible tissue eosinophils in all groups (Fig. 5).

To assess anti-inflammatory effects of AMD3100 on other pro-inflammatory cells, differential cell counts were performed on BAL samples. In WT mice, compared to SAL, there was a significant increase in the total cell count including eosinophils, neutrophils and lymphocytes in WT/HDM group (Table 1). Treatment with AMD3100 did not significantly diminish the HDM-induced inflammatory response in WT mice. Similar findings were also observed in PHIL mice (Table 1).

Airway Responsiveness: HDM exposure increased airway sensitivity to MCh which was attenuated by treatment with AMD3100 in WT and PHIL mice.

Airway responsiveness was assessed by measuring the maximum airway resistance to incremental doses of MCh i.n. in WT and PHIL mice (Fig. 6A&B). A significant increase in maximum resistance to MCh was observed 24 hrs post-allergen in HDM exposed mice compared to the SAL in both WT and PHIL mice and treatment with AMD3100 significantly attenuated this to SAL levels in both groups of mice (Fig. 6C). Although there was a trend for lower airway resistance in PHIL mice compared to WT mice, between group comparisons, showed no significant differences.

Figure 2. Flow cytometric enumeration of lung-extracted primitive progenitor cells. (A) On a dot plot of linear side scatter vs Sca-1 FITC plot, a region R1 was drawn to determine Sca-1+ cells lymphomononuclear cells. From this region events were gated on a dot plot of Sca-1+/c-kit+ cells as shown in Figure panel A. Compared to isotype controls, primitive progenitors were identified as identified as Sca-1+/c-kit+ cells. (B) Lung extracted cells were harvested 24 h after final i.n. challenge with saline (SAL), house dust mite (HDM) or HDM+AMD3100 (n = 10 per group). In WT and PHIL mice, a significant increase in Sca-1+/c-kit+ cells was detected in HDM compared to SAL which was attenuated following treatment with AMD3100. There were significantly lower levels of primitive progenitors in PHIL compared to WT mice. *p < 0.05 compared with SAL; #p < 0.05 compared with HDM; $p < 0.05 compared with WT HDM. Data expressed as mean ± SEM.

doi:10.1371/journal.pone.0109991.g002
Levels of Tissue Associated Cytokines and Pro-angiogenic factors

Tissue Associated levels of VEGF TSLP and IL-33 were determined in supernatants collected from digested lung tissue (n = 10 mice per group) by ELISA in samples collected 24 h post-challenge from all the various treatment groups (Table 2). In both WT and PHIL mice, a significant increase in VEGF levels were detected in HDM compared to SAL group 24 h post Ag-challenge and drug treatment had no effect on these levels. In addition, there were no between group differences observed. TSLP was found to increase significantly in the HDM compared to SAL groups 24 h post Ag-challenge and drug treatment had no effect on these levels. IL-33 levels were not found to be different in the HDM group compared to SAL for both WT and PHIL mice.

Discussion

Asthma has a systemic component involving the mobilisation and lung homing of BM-derived progenitor cells that may contribute to inflammation and tissue remodelling, including angiogenesis [27,28]. Bone marrow-derived EPCs have been shown to contribute to increased bronchial vascularization through in situ differentiation into blood vessels [29] as well as release of proangiogenic factors [30]. Using an ovalbumin challenge model, we have previously shown that inhibiting endothelial progenitor cell accumulation in the lung prevented angiogenic responses and the development of AHR [20]. However, the SDF-1α/CXCR4 axis within the lung, that stimulates the homing of progenitor cells, is also an eosinophil chemoattractant [31] and our study showed that treatment with AMD3100 inhibited allergen-induced airway eosinophilia [20]. It was therefore unclear whether AMD3100 acted directly on EPCs to attenuate lung accumulation or indirectly through its anti-inflammatory effects on eosinophils. The current study tested the hypothesis that lung angiogenesis is an early tissue remodeling event that is independent of eosinophilic inflammation and that mobilization, lung-homing and in-situ differentiation or activation...
of vascular endothelial progenitor cells is a major component of this response.

Using house dust mite, an aeroallergen that is more physiologically relevant to human asthma, this study showed that 1) chronic allergen exposure induces EPC lung-homing, increased bronchial vascularity and development of lung dysfunction in WT BALB/c mice; 2) Similar effects were observed in HDM exposed PHIL mice albeit at lower levels

Figure 4. Microvessel density (MVD) assessed by immunostaining for von Willebrand factor in Lung tissue sections. (A) Images from 24 hrs post-final allergen challenge at 40X magnification. Enumerated vessels were 10 μm in diameter or less (arrows). Scale bars = 50 μm (n = 10 per group) (B) MVD levels increased significantly in HDM compared with SAL groups in both WT and PHIL mice which was attenuated by AMD3100. Between group comparisons showed a trend for lower MVD levels in PHIL versus WT mice (p = 0.058). *p<0.05 compared with SAL; #p<0.05 compared with HDM. Data are expressed as mean ± SEM.
doi:10.1371/journal.pone.0109991.g004

Figure 5. Airway eosinophilia assessed by hematoxylin and eosin stain. In WT mice, house dust mite (HDM) exposure significantly increased eosinophils compared with saline (SAL). This was significantly attenuated by treatment with AMD3100. PHIL mice had negligible numbers of eosinophils. *p<0.05 compared with saline; #p<0.05 compared with HDM. Data are expressed as mean ± SEM. (n = 10 mice per group).
doi:10.1371/journal.pone.0109991.g005
than WT mice suggesting that while the initiation of allergen-induced effects may not be dependent upon eosinophils, the recruitment and activation of eosinophils worsens the pathology of the inflammatory response; 3) Treatment with AMD3100 was comparable in the presence or absence of eosinophils (i.e. in WT and PHIL mice) demonstrating that the SDF-1-CXCR4 axis acts directly on EPC to stimulate lung-homing and promote increased bronchial vascularity and development of airway dysfunction in response to allergen exposure.

As in humans, the murine lung has two blood supplies, the pulmonary and bronchial systems. The functional role of the pulmonary circulation is related to gas exchange while the bronchial circulation provides nutrients and inflammatory cells to the peripheral lung via oxygenated blood from the systemic circulation. Gross anatomic studies have long demonstrated bronchial arteries supplying bronchial and structural tissues of the murine lung. The concept of the bronchial arteries also supplying the peripheral lung in mice has been suggested by the presence of lung structure in the presence of pulmonary artery

| Table 1. Airway inflammation as measured by bronchial alveolar lavage (BAL). |
|-----------------------------------------|-----------------|-----------------|-----------------|
|                                        | WT              | PHIL            |                 |
|                                        | SAL             | HDM             | HDM + AMD3100   | SAL             | HDM             | HDM + AMD3100   |
| TCC ×10⁶                                | 3.37±0.54       | 9.20±1.60*      | 6.87±0.77**     | 4.13±0.48       | 6.83±0.51*      | 5.69±0.28*      |
| Eosinophils                             | 0.01±0.01       | 2.85±0.47*      | 2.05±0.14*      | 0±0             | 0.02±0.01       | 0.00±0.00       |
| Neutrophils                             | 0.19±0.06       | 1.15±0.32*      | 1.35±0.16*      | 0.18±0.04       | 1.33±0.31*      | 1.24±0.14*      |
| Macrophages                             | 2.65±0.53       | 2.87±0.46       | 1.66±0.20       | 3.37±0.43       | 3.03±0.27       | 2.52±0.16       |
| Lymphocytes                             | 0.52±0.06       | 2.36±0.59*      | 1.80±0.27*      | 0.59±0.13       | 2.46±0.29*      | 1.92±0.30*      |

Data are presented as mean ± SEM. TCC: total cell count. Cells were counted in bronchoalveolar lavage samples collected from WT and PHIL mice (n = 10 per group) sensitized by chronic exposure protocol with concurrent treatment with AMD3100. Measurements were made at 24 h after saline (SAL), house dust mite (HDM), or HDM + AMD3100 challenge. *p<0.05 compared to SAL. Data are expressed as mean ± SEM.

Figure 6. Airway responsiveness as measured by resistance to intranasal methacholine. Airway resistance curves to methacholine for (A) WT and (B) PHIL mice; (C) Maximal airway resistance in response to 25 mg/mL methacholine in WT and PHIL mice. Data are presented as the maximal resistance between 3.1–25 mg/mL minus the baseline value (0 mg/mL) for each mouse. In WT and PHIL mice, there was a significant increase in methacholine airway responsiveness in HDM versus SAL in WT and PHIL mice. This was significantly attenuated by treatment with AMD3100. Data are expressed as mean ± SEM. *p<0.05 compared with SAL; #p<0.05 compared with HDM.

doi:10.1371/journal.pone.0109991.t001
doi:10.1371/journal.pone.0109991.g006
obstruction [32]. A study by Ravnic et al., detailed murine bronchopulmonary microcirculation and provided morphological evidence for (i) peripheral bronchial circulation, (ii) interconnections between bronchial and pulmonary circulation in the distal bronchial arteries and at the level of the alveolar capillaries both arising at vessels <20 μm diameter, and (iii) functional evidence of increased bronchial perfusion to alveolar capillaries during a peripheral mononuclear inflammatory response to intratracheal installation of peptide-hapten triptonophenol demonstrating an adaptive role of the bronchial circulation in pulmonary inflammation [33]. The latter findings are consistent with clinical findings of bronchial hyperplasia in chronic inflammatory disorders.

In the current study we stained newly formed microvessels with vWF which is a glycoprotein that is essential for blood coagulation and vessel wall repair that is stored in Weibel-Palade bodies within the cytoplasm of endothelial cells [34]. Comparative immunohistochemical staining and confocal laser microscopy of vWF throughout varying calibers of pulmonary vasculature have shown that vWF is a consistent positive marker for all vessels greater than 10 μm and is undetectable in alveolar capillary endothelial cells, but is highly expressed in venules [32,35]. These vessels sizes support our own determination of newly formed microvessels within a 50 μm bandwidth from the airway and ≤10 μm in diameter. By this method we have shown that there is a significant increase in bronchial vascularity in murine lung following HDM challenge in sensitized WT and PHIL mice. In addition, we and others have previously demonstrated a rapid and sustained allergen-induced lung homing of EPCs which correlated with increased bronchial vascularity and airway resistance following ovalbumin exposure in sensitized WT mice [15,20]. In addition, kinetic studies showed the EPC recruitment preceded the onset of lung vascularization and airway eosinophilia [15]. Further studies in this model showed that lung-extracted EPC expressed eotaxin which could in-turn recruited eosinophils to the site of inflammation [36]. More recently, nascent epithelial cells have been shown to promote Th2 responses suggesting that EPCs homing to the lung in response to allergen challenge may act as early initiators of allergic inflammatory responses [37]. The current study shows for the first time that HDM-exposure induced increases in lung-extracted EPC and bronchial vascularity 24h post-Ag challenge in both WT and eosinophil deficient PHIL mice. Comparable changes in airway resistance are consistent with previous studies [38]. This suggests that allergen exposure in PHIL mice results in lung remodelling changes even in the absence of eosinophils albeit at lower levels compared to WT mice. Thus although eosinophils are not necessary for the onset of airway disease, they do appear to contribute to worsening the lung remodelling changes in WT mice. This is in line with previous findings that eosinophil-derived granule proteins and cell derived factors (angiogenin, VEGF, and NGF) have pro-angiogenic effects and can stimulate lung vascularization [39–41].

In this study, AMD3100 was administered i.n. during the chronic phase of the HDM exposure model so as to localize the drug effects to the lung. Assessment of the lung tissue showed that drug treatment attenuated allergen-induced lung EPC levels in WT mice and PHIL mice to saline levels. Similarly, AMD3100 significantly attenuated MVD levels in PHIL mice to saline levels indicating that increased accumulation of EPC may directly form tube-like structures or promote local angiogenic responses by stimulating proliferation of existing vascular endothelial cells in response to allergen challenge in the absence of eosinophils [42] [43] [28]. By comparison in WT mice, MVD levels were significantly increased compared to SAL levels in HDM group, and treatment with AMD3100 attenuated these numbers although not to saline levels (Fig. 4). Since HDM-induced eosinophil numbers in the peribronchial region were not completely abrogated by treatment with AMD3100 (Fig. 5), it is likely that eosinophil-derived products may also play a role in promoting the local vasculatization of the lungs. This is supported by the fact that vasculatization is attenuated to saline levels in the PHIL mice that lack eosinophils but not in WT mice (Fig. 4).

In the current study, BAL eosinophilia in WT mice treated with the drug, AMD3100 remained elevated (Table 1), contrary to the reduction of airway eosinophilia reported in our previous OVA-challenge study [20,39]. Differences in the effect of the drug on Ag-induced airway eosinophilia (taken from BAL fluid) between OVA and HDM models maybe be caused by the fact that HDM exposed mice develop a more robust eosinophilia that is not as easily attenuated as that seen in OVA-exposed mice. In a study comparing OVA and HDM chronic exposure models in BALB/c mice, the magnitude of the airway eosinophilia was found to be approximately 3 times greater in HDM mice 24hours post allergen exposure [44]. The robust eosinophilia seen in HDM exposed mice may be caused by HDM activating the airway epithelium through the innate immune pathway in addition to activation of the adaptive immune response. It has been shown that HDM-associated ligands (such as proteases Der p 2,7 and endotoxin) are recognize by TLR-4 (toll-like receptor 4) which can stimulate airway epithelial cells to produce TSLP, IL-25, and IL-33. These TLR-4 products further promote inflammatory cell (i.e. eosinophil) accumulation into the lungs, activate dendritic cells

### Table 2. Lung Tissue Associate Levels of Pro-Angiogenic Cytokines and Chemokines.

| Phyotypic Factor Levels (pg/ml) | WT   | PHIL     |
|-------------------------------|------|----------|
|                               | SAL  | HDM      | HDM+AMD3100 |
|                               | SAL  | HDM      | HDM+AMD3100 |
| VEGF                          | 1740±190 | 3460±420* | 3660±230* | 1850±170 | 2730±220* | 2430±340* |
| TSLP                          | 54.7±2.1 | 158±12.7* | 149±12.6* | 48.7±3.06 | 175±17.6* | 149±13.07* |
| IL-33                         | 27.6±1.2 | 30±2.3   | 26±2.3   | 25.3±1.68 | 36±3.4   | 35±3.3    |

Tissue Associated levels of Vascular endothelial derived growth factor (VEGF), TSLP and IL-33 were determined in supernatants collected from digested lung tissue (n = 10 mice per group) by ELISA in samples collected 24 h post-challenge. In WT and PHIL mice, there is a significant increase in levels of VEGF and TSLP that were not attenuated by treatment with AMD3100 in both groups of mice. Compared to SAL, there was no allergen-induced production of IL-33 in either WT or PHIL mice. *: p<0.05 compared with saline (SAL); Data are presented as mean ± SEM.

doi:10.1371/journal.pone.0109991.T002
lung attenuated angiogenesis and the development of AHR. Our inflammatory responses. The role of epithelial-derived cytokines in promoting EPC migration and angiogenic response since the lungs has been reported. In this study we show that following HDL challenge there is a significant increase in TSLP production in the WT mice reported. In this study we show that following HDM challenge increased lung-homing of eosinophils compared to ovalbumin challenge.

In summary, we report that modulating EPC traffic into the lung attenuated angiogenesis and the development of AHR. Our data indicate that EPC recruitment to the lungs in allergic inflammatory responses is mediated by CXCR4/SDF-1 axis acting directly on the progenitor cells. In addition, we have shown that while Ag-induced lung accumulation of EPC and increased lung vascularization can occur in the absence of eosinophils as seen in PHIL mice, the presence of these cells may have a role in worsening of the pathology of allergic airways disease.

Supporting Information

Data S1 Data and Stats. (XLSX)

Author Contributions

Conceived and designed the experiments: MD RS. Performed the experiments: NS JW. Analyzed the data: NS RS. Contributed reagents/materials/analysis tools: RS. Wrote the paper: NS RS.

References

1. Pascual RM, Peters SP (2005) Airways remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 116: 477–486.
2. Jeffery PK (2001) Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164: 820–830.
3. Mannikam W, Howarth PH, Holgate ST (2013) Airways remodeling in asthma and novel therapy. Asian Pac J Allergy Immunol 31: 3–10.
4. Wilson JW, Hii S (2006) The importance of the airway microvasculature in asthma. Curr Opin Allergy Clin Immunol 6: 51–53.
5. Wilson JW, Kotimbos TG (2003) Airway Vascular Remodeling in Asthma. Current Allergy and Asthma Reports 3: 153–158.
6. Chetta A, Zanini A, Torre O, Olivieri D (2006) Vascular Remodeling and Angiogenesis in Asthma: Morphological Aspects and Pharmacological Modulation. Inflammation & Allergy – Drug Targets 6: 41–45.
7. Toveley RG, Hoviba M (2003) Airway Hyperresponsiveness: A story of mice and men and cytokines. Clinical Reviews in Allergy and Immunology 24: 83–109.
8. Paredi P, Barnes PJ (2009) The airway vasculature: recent advances and clinical implications. Thorax 64: 444–450.
9. McFadden ER (1990) Hypothesis: exercise-induced asthma as a vascular phenomenon. Lancet 335: 880–883.
10. Hogg JC, Pare PD, Moreno R (1987) The effect of submucosal edema on airways resistance. Am Rev Respir Dis 135: S54–S56.
11. Panda CM, Dhillon NS, Sanzati DD (2006) Angiogenesis – a new target for future therapy. Vascular Pharmacology 44: 265–274.
12. Yoder MC (2010) Is endothelium the origin of endothelial progenitor cell. Arterioscler Thromb Vasc Biol 30: 1094–1103.
13. Lipstein A, Verfaillie CM (2007) Will the real EPC please stand up? Blood 109: 1759–1766.
14. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, et al. (2007) Redefining endothelial progenitor cell via clonal analyses and hematopoietic stem/progenitor cell principals. Blood: 1801–1809.
15. Assoulih K, Swaidani S, Aronica M, Erzurum SC (2007) Th1- and Th2-dependent endothelial progenitor cell recruitment and angiogenic switch in asthma. J Immunol 178: 6366–6374.
16. Imaoka H, Punia N, Iqbal Y, Corgian C, et al. (2011) Lung homing of endothelial progenitor cells in humans with asthma following allergen challenge. Am J Respir Crit Care Med 184: 1–15.
17. Jones CP, Pitchford SC, Lloyd CM, Rankin SM (2009) CXCR2 mediates the recruitment of endothelial progenitor cells during allergic airway remodeling. Stem Cells 1: 1–15.
18. Corgian C, Wang W, Meng Q, Fang C, Wu H, et al. (2011) TH2 helper cell type 2 (TH2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci U S A 108: 1579–1584.
19. Gregory LG, Jones CP, Walker SA, Sawant D, Gowers KH, et al. (2013) IL-25 drives remodeling in allergic airways disease induced by house dust mite. Thorax 68: 82–90.
20. Doyle TM, Ellis R, Park HI, Peng K, Inman MD, et al. (2011) Modulating progenitor cell accumulation attenuates lung angiogenesis in a mouse model of asthma. European Respiratory Journal 38: 679–687.
21. Lee JJ, Diminna D, Macias MP, Ochukri SI, McGarry MP, et al. (2004) Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305: 1773–1776.
22. Southam DS, Ellis R, Wattie J, Inman MD (2007) Components of airway hyperresponsiveness and their association with inflammation and remodeling in mice. J Allergy Clin Immunol 119: 848–854.
42. Larrivee B, Nissen K, Pollet I, Corbel SY, Long M, et al. (2005) Minimal Contribution of Marrow-Derived Endothelial Precursors to Tumor Vasculature. The Journal of Immunology 175: 2890–2899.
43. Gao DD, Nolan DJ, Mellick AS, Bambino K, McDonnell K, et al. (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195–198.
44. DiGiovanni F, Ellis R, Wattie J, Hirota J, Southam D, et al. (2009) Concurrent dual exposure and its effects on airway hyperresponsiveness, inflammation and remodeling in mice. Disease Models and Mechanisms 2: 275–282.
45. Lambrecht BN, Hammad H (2012) The airway epithelium in asthma. Nature Medicine 18: 684–692.